Physician profile
Smitha R Pamulaparthy
NPI 1447328828
$2,199.92
in general payments reported to CMS, 2019-2025
14 companies · $16.58 in 2025
The $16.58 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $274 · 2021: $361 · 2022: $449 · 2023: $405 · 2024: $445 · 2025: $16.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854 · Education: $12.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.91 |
| Education | $12.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $439.14 | 2020-2023 | Jynarque |
| Vifor Pharma, INC. | $300.39 | 2020-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $296.36 | 2019-2025 | Farxiga |
| Horizon Therapeutics Plc | $263.52 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $233.57 | 2023-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $188.48 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.65 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $121.85 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $116.20 | 2023 | Jesduvroq |
| Mallinckrodt Hospital Products INC. | $42.58 | 2020 | |
| Dexcom, INC. | $22.52 | 2021 | |
| Fresenius USA Marketing, INC. | $19.75 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $19.17 | 2021 | |
| Akebia Therapeutics INC | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Pamulaparthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.